Ang-(1-12)/Chymase轴:新型胞内分泌机制为治疗开辟新方向  

Angiotensin-(1-12)/Chymase Axis:Novel Intracrine Mechanism for Opening a New Era of Therapy

作　　者：吴佳欣 谢旭东[1] WU Jiaxin;XIE Xudong(Department of Cardiology,The First Affiliated Hospital of Zhejiang University,Hangzhou 310003,Zhejiang,China)

机构地区：[1]浙江大学附属第一医院心血管内科

出　　处：《心血管病学进展》2019年第8期1090-1094,共5页Advances in Cardiovascular Diseases

摘　　要：随着肾素-血管紧张素系统肽谱的逐渐丰富,传统的肾素-血管紧张素系统正在经历重大的修正。研究发现目前正在广泛使用的血管紧张素系统抑制剂对心脏疾病的有益作用低于预期,这导致新的由非肾素途径介导的、具有高度特异性和组织/细胞依赖性的血管紧张素Ⅱ形成机制的提出。现综述血管紧张素-(1-12)是细胞内血管紧张素Ⅱ的主要替代底物,独立于循环肾素-血管紧张素系统,以及糜蛋白酶作为转化酶在其中的关键作用。With the gradual enrichment of the peptide spectrum of renin-angiotensin system,the traditional renin-angiotensin system is undergoing major corrections.The study found that the currently widely used angiotensin system inhibitors have less beneficial effects in the heart diseases than expected,and this leads to the new proposal of mechanism of angiotensinⅡformation mediated by non-renin pathways,with high specificity and histo/cell dependence.This review addresses that angiotensin-(1-12),as a major endogenous substrate of intracellular angiotensinⅡ,is independent of the circulating renin-angiotensin system,and chymase is as a key enzyme in the heart.

关 键 词：血管紧张素-(1-12) 糜蛋白酶 肾素-血管紧张素系统 血管紧张素肽 胞内分泌 

分 类 号：R73[医药卫生—肿瘤]